Poseida Therapeutics Stock
Genome engineering-enabled therapeutics
Sign up today and learn more about Poseida Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Poseida Therapeutics Stock
Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need. It has demonstrated proof-of-principle that validates the potential of its differentiated genome engineering technologies and their therapeutic applications. The company's technology platforms have broad applicability and Poseida’s long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases.
Chief Technology Officer
Paiman Peter Ghoroghchian
Chief Executive Officer
Chief Medical Officer
Chief Human Resources Officer
President and Chief Operating Officer
Nishan de Silva
Chief Business Officer and Chief Financial Officer
Mark J. Gergen